IMUNEXINTM MULTISPECIFIC ANTIBODIES: WHAT ARE THEY?
A normal monoclonal antibody can bind to one specific therapeutic target (i.e. it has one specificity). Our multispecifics are engineered proteins that are composed of imunexinsTM genetically fused to a parent antibody. imunexinsTM can be fused to the constant heavy and/or to the constant light regions of an antibody. One pair of imunexinsTM fused to an antibody generates a bispecific (i.e. it has two specificities) while two pairs of imunexinsTM with different binding specificities fused to an antibody generate a trispecific (i.e. it has three specificities).
Diagram showing a monospecific antibody converted into a bispecific antibody by genetically fusing imunexinsTM
to the antibody constant region (elements not drawn to scale)
Diagram showing a monospecific antibody converted into a trispecific antibody by genetically fusing imunexinsTM
to the antibody constant regions (elements not drawn to scale)
POTENTIAL APPLICATIONS FOR MULTISPECIFIC ANTIBODIES:
Multispecific antibodies have the potential to become important therapeutics for a number of diseases. Some of the potential applications for multispecifics are outlined:
- Redirect and activate immune effector cells to specifically kill tumours.
- Bind to multiple targets and effect multiple pathogenic pathways.
- Bind to multiple sites on the one target cell or protein to increase specificity or induce synergistic induction.
- Target tumours that are heterogeneous.
- Increase the half-life of whole antibodies, antibody fragments, or other proteins.
- Bind to transport proteins to allow antibodies to cross biological barriers.